Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026

Same author

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.

JAMA neurology·2026

Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026

Same author

The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints.

medRxiv : the preprint server for health sciences·2026

Same author

Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026

Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026

Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026

Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026

Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026

Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

Bapineuzumab.

Geoffrey A Kerchner¹, Adam L Boxer

¹Stanford University School of Medicine, Stanford Center for Memory Disorders, 300 Pasteur Drive, Room A343, Stanford, CA 94305-5235, USA.

Expert Opinion on Biological Therapy

|May 26, 2010

Summary

This summary is machine-generated.

Bapineuzumab, an Alzheimer's disease immunotherapy, may reduce beta-amyloid but its efficacy in slowing progression is uncertain, especially in APOE 4 carriers. Vasogenic edema is a potential safety concern.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Related Experiment Videos

Last Updated: Jun 12, 2026

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Area of Science:

Neuroscience
Immunology
Geriatrics

Background:

Alzheimer's disease (AD) is the primary cause of dementia in older adults, with no current disease-modifying treatments.
Immunotherapy targeting beta-amyloid peptides offers a potential strategy to slow AD progression.
Bapineuzumab, an anti-beta-amyloid monoclonal antibody, represents a leading immunotherapy candidate in late-stage clinical trials.

Purpose of the Study:

To review the literature on bapineuzumab and related Alzheimer's disease immunotherapies.
To critically appraise Phase II trial results for bapineuzumab.
To discuss the broader landscape and challenges of Alzheimer's disease immunotherapy.

Main Methods:

Comprehensive review of primary literature on bapineuzumab (2009-2010).
Review of literature on AN1792, a first-generation anti-beta-amyloid vaccine (2003-2009).
Inclusion of data on other AD immunotherapeutics in development from clinicaltrials.gov.

Main Results:

Bapineuzumab demonstrated the ability to reduce cerebral beta-amyloid peptide burden in AD patients.
Efficacy of bapineuzumab in slowing disease progression remains uncertain, particularly in APOE 4 carriers.
Vasogenic edema was identified as a dose-limiting and potentially severe adverse reaction.

Conclusions:

Bapineuzumab shows potential for amyloid reduction in Alzheimer's disease.
Clinical applicability may be limited by uncertain efficacy in slowing progression and the risk of vasogenic edema.
Further research is needed to address safety and efficacy in specific patient populations.